New CEO to drive NNIT’s continued strategic journey
Today, NNIT’s Board of Directors have entered into an agreement with Pär Fors who will join NNIT as CEO as of June 14, 2021. Pär Fors will replace Per Kogut who has served as NNIT’s CEO since 2007.
-
-
Financial results for Q1 2021 just released: Group revenue up 1.2%
In Q1, we experienced continued strong growth within the International Life Sciences business, with Excellis performing to plan. Our Private & Public business started to see positive momentum in relation to the Winning Solutions strategy, which now constitutes 49% of NNIT’s revenue.
-
Lonza and NNIT partner to speed up MES projects
Across the life sciences industry, pharma companies are seeking new ways to respond to the high agility required to produce complex products like personalized cancer treatment, cell and gene therapy and Covid-19 vaccines. Central to these efforts is the manufacturing execution system (MES), which allows pharma companies to adopt pharma 4.0 production and manage their data flows to expedite product
-
NNIT and SCALES enter into a contract with Norlys for the development and implementation of one consolidated Microsoft ERP solution
Under the heading ”OneERP,” NNIT and its subsidiary SCALES will start a project with Norlys to consolidate a number of existing Dynamics and AX solutions into Microsoft Dynamics365 for Finance and Operations.
-
NNIT og SCALES indgår kontrakt med Norlys om udvikling og implementering af én samlet Microsoft ERP-løsning
Under overskriften ”OneERP” indleder NNIT og datterselskabet SCALES nu et projekt sammen med Norlys, hvor opgaven er at konsolidere et antal eksisterende Dynamics og AX-løsninger til Microsoft Dynamics365 for Finance and Operations.
-
Kvartalsrapport for Q4 2020 og årsrapport 2020 netop udkommet
NNIT formåede at holde guidance i 2020. Q4 bidrog med tocifret organisk og profitabel vækst inden for Life Sciences International-forretningen, og opkøbet af Excellis bidrog yderligere til denne vækst.
-
Interim financial report for Q4 2020/Annual Report just released
NNIT concluded 2020 in line with the financial guidance. Q4 contributed an organic double digit, profitable growth within the Life Sciences International business. The acquisition of Excellis positively added further growth.
-
NNIT to support COVID-19 vaccine safety data capture
NNIT, a trusted partner of AstraZeneca’s since 2014, will be implementing the critical COVID-19 vaccine post-marketing safety data system.
-
NNIT skal understøtte dokumentationen af sikkerhedsdata for COVID-19 vaccine
NNIT har siden 2014 været en af AstraZenecas betroede leverandører og skal nu stå for det kritiske arbejde med implementeringen et sikkerhedsdatasystem i forbindelse med markedsføringen af deres COVID-19 vaccine.
-
Opkøbs-boostet Orifarm vælger NNIT som ny strategisk it-partner
Orifarm og NNIT har underskrevet en kontrakt omkring leveringen af end-to-end it-tjenester i forbindelse med Orifarms opkøb af en betydelig portefølje bestående af udvalgte over-the-counter (OTC) og receptpligtige lægemidler fra den japanske lægemiddelkæmpe Takeda.
-
Acquisition-boosted Orifarm selects NNIT as new strategic IT partner
Orifarm and NNIT have signed a contract for the delivery of end-to-end IT services in connection with Orifarm’s acquisition of a significant portfolio of select over-the-counter (OTC) and prescription pharmaceutical products from Japanese pharmaceutical giant Takeda.
-
NNIT-gruppen køber Excellis Health Solutions og fortsætter sin Life Sciences-vækstrejse
NNIT køber den amerikanske virksomhed Excellis, som er en ledende og specialiseret global udbyder af end-to-end supply chain konsulentydelser til life sciences-industrien.
Show more
Loading...